Document Detail

Immunotherapeutic strategies in chronic myeloid leukemia.
MedLine Citation:
PMID:  20425356     Owner:  NLM     Status:  MEDLINE    
Several clinical observations demonstrate that immunologic effects are important in chronic myeloid leukemia (CML). The characteristic BCR-ABL fusion protein is a leukemia-specific antigen, and it has therefore received much immunologic attention, especially regarding the amino acid sequences that span the e14a2 junction. Other attractive targets are the Wilms' tumor 1 antigen and the PR1 epitope from proteinase 3, a granule protein overexpressed in CML. Imatinib may modulate several components of the immune response, although the clinical relevance of this effect is uncertain. In clinical trials, peptide vaccination appears safe and undoubtedly produces clinical effects, but randomized trials are now required to see if these are distinct from the effects of other concurrent therapy. These trials will be difficult to orchestrate in the competitive environment of novel therapies for CML.
Richard E Clark
Related Documents :
15491976 - Cd163: a specific marker of macrophages in paraffin-embedded tissue samples.
234296 - New looks in leukemia.
3159446 - Phenotypic analysis of acute lymphoblastic leukemia (all) cells which are classified as...
1331626 - Antibodies to human herpes virus-6 in patients with acute lymphocytic leukemia.
7515336 - The presence of peptidoglycan-polysaccharide complexes in the bowel wall and the cellul...
11839246 - Molecular characterization of human monoclonal antibodies derived from fusions of tonsi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current hematologic malignancy reports     Volume:  2     ISSN:  1558-822X     ISO Abbreviation:  Curr Hematol Malig Rep     Publication Date:  2007 May 
Date Detail:
Created Date:  2010-04-28     Completed Date:  2010-08-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101262565     Medline TA:  Curr Hematol Malig Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  89-94     Citation Subset:  IM    
Department of Haematology, Royal Liverpool University Hospital, Prescot St., Liverpool L7 8XP, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, Neoplasm / chemistry,  immunology*
Cancer Vaccines / immunology,  therapeutic use*
Clinical Trials as Topic
Clonal Anergy
Dendritic Cells / drug effects,  immunology
Epitopes / chemistry,  immunology
Fusion Proteins, bcr-abl / chemistry,  genetics,  immunology
Immunotherapy / methods*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics,  immunology,  therapy*
Myeloblastin / chemistry,  immunology
Neoplasm Proteins / chemistry,  genetics,  immunology*
Peptide Fragments / chemistry,  immunology
Piperazines / pharmacology,  therapeutic use
Protein Kinase Inhibitors / pharmacology,  therapeutic use
Pyrimidines / pharmacology,  therapeutic use
T-Lymphocyte Subsets / immunology
Vaccines, Subunit / immunology,  therapeutic use
WT1 Proteins / chemistry,  immunology
Reg. No./Substance:
0/Antigens, Neoplasm; 0/Cancer Vaccines; 0/Epitopes; 0/Fusion Proteins, bcr-abl; 0/Neoplasm Proteins; 0/Peptide Fragments; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 0/Vaccines, Subunit; 0/WT1 Proteins; 152459-95-5/imatinib; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Next Document:  Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia.